Literature DB >> 24142344

ALDH1-positive cancer stem cells predict engraftment of primary breast tumors and are governed by a common stem cell program.

Emmanuelle Charafe-Jauffret1, Christophe Ginestier, François Bertucci, Olivier Cabaud, Julien Wicinski, Pascal Finetti, Emmanuelle Josselin, José Adelaide, Tien-Tuan Nguyen, Florence Monville, Jocelyne Jacquemier, Jeanne Thomassin-Piana, Guillaume Pinna, Aurélie Jalaguier, Eric Lambaudie, Gilles Houvenaeghel, Luc Xerri, Annick Harel-Bellan, Max Chaffanet, Patrice Viens, Daniel Birnbaum.   

Abstract

Cancer stem-like cells (CSC) have been widely studied, but their clinical relevance has yet to be established in breast cancer. Here, we report the establishment of primary breast tumor-derived xenografts (PDX) that encompass the main diversity of human breast cancer and retain the major clinicopathologic features of primary tumors. Successful engraftment was correlated with the presence of ALDH1-positive CSCs, which predicted prognosis in patients. The xenografts we developed showed a hierarchical cell organization of breast cancer with the ALDH1-positive CSCs constituting the tumorigenic cell population. Analysis of gene expression from functionally validated CSCs yielded a breast CSC signature and identified a core transcriptional program of 19 genes shared with murine embryonic, hematopoietic, and neural stem cells. This generalized stem cell program allowed the identification of potential CSC regulators, which were related mainly to metabolic processes. Using an siRNA genetic screen designed to target the 19 genes, we validated the functional role of this stem cell program in the regulation of breast CSC biology. Our work offers a proof of the functional importance of CSCs in breast cancer, and it establishes the reliability of PDXs for use in developing personalized CSC therapies for patients with breast cancer. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24142344     DOI: 10.1158/0008-5472.CAN-12-4704

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

Review 1.  Two Sides of the Same Coin: The Role of Developmental pathways and pluripotency factors in normal mammary stem cells and breast cancer metastasis.

Authors:  M U J Oliphant; Deguang Kong; Hengbo Zhou; M T Lewis; H L Ford
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-04-22       Impact factor: 2.673

2.  Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.

Authors:  Masaya Kai; Noriko Kanaya; Shang V Wu; Carlos Mendez; Duc Nguyen; Thehang Luu; Shiuan Chen
Journal:  Breast Cancer Res Treat       Date:  2015-04-23       Impact factor: 4.872

3.  Barriers to generating PDX models of HPV-related head and neck cancer.

Authors:  Nicole D Facompre; Varun Sahu; Kathleen T Montone; Kayla M Harmeyer; Hiroshi Nakagawa; Anil K Rustgi; Gregory S Weinstein; Phyllis A Gimotty; Devraj Basu
Journal:  Laryngoscope       Date:  2017-05-31       Impact factor: 3.325

4.  Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer.

Authors:  Chaofeng Mu; Xiaoyan Wu; Xinyu Zhou; Joy Wolfram; Jianliang Shen; Dechen Zhang; Junhua Mai; Xiaojun Xia; Ashley M Holder; Mauro Ferrari; Xuewu Liu; Haifa Shen
Journal:  Clin Cancer Res       Date:  2018-06-19       Impact factor: 12.531

5.  Distinct prognostic values of ALDH1 isoenzymes in breast cancer.

Authors:  Shaokun Wu; Weiping Xue; Xiaobo Huang; Xiaoli Yu; Ming Luo; Ying Huang; Yimin Liu; Zhuofei Bi; Xingsheng Qiu; Shoumin Bai
Journal:  Tumour Biol       Date:  2015-01-13

6.  Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas.

Authors:  Timothy Henderson; Mingyi Chen; Morgan A Darrow; Chin-Shang Li; Chi-Lu Chiu; Arta M Monjazeb; William J Murphy; Robert J Canter
Journal:  J Surg Res       Date:  2017-12-22       Impact factor: 2.192

7.  Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers.

Authors:  Noriko Kanaya; George Somlo; Jun Wu; Paul Frankel; Masaya Kai; Xueli Liu; Shang Victoria Wu; Duc Nguyen; Nymph Chan; Meng-Yin Hsieh; Michele Kirschenbaum; Laura Kruper; Courtney Vito; Behnam Badie; John H Yim; Yuan Yuan; Arti Hurria; Chu Peiguo; Joanne Mortimer; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2016-05-03       Impact factor: 4.292

Review 8.  Interrogating open issues in cancer precision medicine with patient-derived xenografts.

Authors:  Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino
Journal:  Nat Rev Cancer       Date:  2017-01-20       Impact factor: 60.716

9.  Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure.

Authors:  Pierre-Emmanuel Colombo; Stanislas du Manoir; Béatrice Orsett; Rui Bras-Gonçalves; Mario B Lambros; Alan MacKay; Tien-Tuan Nguyen; Florence Boissière; Didier Pourquier; Frédéric Bibeau; Jorge S Reis-Filho; Charles Theillet
Journal:  Oncotarget       Date:  2015-09-29

10.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype.

Authors:  Erik Ames; Robert J Canter; Steven K Grossenbacher; Stephanie Mac; Mingyi Chen; Rachel C Smith; Takeshi Hagino; Jessica Perez-Cunningham; Gail D Sckisel; Shiro Urayama; Arta M Monjazeb; Ruben C Fragoso; Thomas J Sayers; William J Murphy
Journal:  J Immunol       Date:  2015-09-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.